A review of life science current events reported by MedCity News this week:
Mayo Clinic’s magic misused. And a Minnesota incubator crumbles. “A Minnesota incubator created to commercialize technology from Mayo Clinic and similar institutions is being dismantled less than two years after its launch. Plus, Mayo charges that its name was improperly leveraged for fundraising purposes, a charge confirmed by the spokesman of the incubator: Healthcare IP Partners.”
Health IT firm Ascom gets 510(k) clearance on patient alert system. “A medical alert system developed by wireless communications company Ascom has received 510(k) clearance from the U.S. Food and Drug Administration, and now the company is gearing up to bring the new offering to its installed customer base of nearly 1,200 U.S. hospitals.”
Inside an Automated Healthcare Practice: Redesigning Care Around People, Not Paperwork
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.
“Cleveland-backed Israeli device firm gets FDA clearance. Israeli company Navotek Medical, which is backed by a Cleveland venture firm, has received U.S. regulatory clearance for its radiation therapy monitoring system.”
Talecris blood clot treatment gets orphan drug designation in Europe. “A blood clot treatment being developed by Talecris Biotherapeutics has received an orphan drug designation from European regulators. Research Triangle Park, North Carolina-based Talecris (NASDAQ:TLCR) is studying Plasmin in phase II clinical trials to assess its ability to treat acute peripheral arterial occlusion, or aPAO. The condition occurs when blood flow to the extremities, usually the legs, is blocked by a blood clot. It is most common in people with underlying peripheral artery disease.”